Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.

Howard A. Burris,Margaret K. Callahan,Anthony W. Tolcher,Shivaani Kummar,G. S. Falchook,Russell Pachynski,Scott S. Tykodi,Geoffrey T. Gibney,Tanguy Y. Seiwert,Justin F. Gainor,Patricia LoRusso,James Hilbert,Josh F Apgar,Fei Hua,John M. Burke,Manny Lazaro,Myles Clancy,Baoyu Ding,Elizabeth Trehu,Timothy A. Yap

Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.

2017

3033Background: JTX-2011 is an agonist monoclonal antibody that targets ICOS, Inducible CO-Stimulator of T cells. A dual mechanism of action is intended to activate antigen-specific CD4 T effector ...

Keywords:

Antibody
Nivolumab
Cancer research
Agonist
Pathology
Medicine
Pharmacokinetics
dual mechanism
Effector
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations